(Formerly known as, Sotac Pharmaceuticals Private Limited) Registered Office : Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GICD - II, Sanand, Ahmedabad – 382110, Gujarat (INDIA)

SOTAC PHARMACEUTICALS LIMITED

CIN.: L24230GJ2015PLC085451



Date: May 29, 2023

**To, Listing Compliance Department National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex Bandra East, Mumbai-400051

Dear Sir,

Sub: Outcome of board meeting held on today i.e. On Monday May 29, 2023, In Terms Of Second Proviso to Regulation 30(6) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

# Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e. on Monday May 29, 2023, at the Registered Office of the Company which was commenced at 04:00 P.M. and concluded at 05:00 P.M., have;

- 1. Considered, approved and taken on record the Audited Standalone & Consolidated financial results for the half year ended and year ended on March 31, 2023 along with Audit Report (Unmodified Opinion) and Declaration by the Company for the Audit Report with Unmodified Opinion;
- 2. Consider, approve & take on record the Audited Standalone & Consolidated Financial Statement of the Company for the financial year ended on March 31, 2023 in accordance with the Companies Act, 2013;
- 3. Appointed M/s. SCS and Co. LLP, Practicing Company Secretary, Ahmedabad as Secretarial Auditor for Secretarial Audit of the Company for the F.Y. 2023-24.
- 4. Appointed M/s. Amit G Patel & Associates Chartered Accountant (FRN: 152837W), Ahmedabad as Internal Auditor for Internal Audit of the Company for the F.Y. 2023-24.
- 5. Considered and approved all other business as per agenda circulated.

Brief Profile of M/s. SCS and Co. LLP, Practicing Company Secretary and M/s. Amit G Patel & Associates Chartered Accountant are enclosed herewith as Annexure-I

Kindly take the same on your record and oblige us.

Thanking you

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel Chairman and Managing Director DIN: 07252252 Place: Ahmedabad (Formerly known as, Sotac Pharmaceuticals Private Limited) Registered Office : Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GICD - II, Sanand, Ahmedabad – 382110, Gujarat (INDIA)

SOTAC PHARMACEUTICALS LIMITED

CIN.: L24230GJ2015PLC085451

SOTAC

Date: May 29, 2023

To, Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra East, Mumbai-400051

Dear Sir,

Sub: Submission of Standalone & Consolidated Audited Financial Result of the Company for the half year and year ended on March 31, 2023 along with Auditor Report (Unmodified Opinion) and Declaration for the Auditor's Report with Unmodified Report.

## Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:

- 1. Standalone & Consolidated Audited Financial Results for the half year and year ended on March 31, 2023.
- 2. Statement of Standalone & Consolidated Audited Asset & Liabilities for the year ended as at March 31, 2023.
- 3. Standalone & Consolidated Cash Flow Statement for the year ended as at March 31, 2023.
- 4. Audit Report (unmodified opinion) on the Audited Financial Results.
- 5. Declaration by the Company (for audit report with unmodified opinion).

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel Chairman and Managing Director DIN: 07252252

Place: Ahmedabad

(Formerly known as, Sotac Pharmaceuticals Private Limited) Registered Office : Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GICD - II, Sanand, Ahmedabad – 382110, Gujarat (INDIA)

SOTAC PHARMACEUTICALS LIMITED

CIN.: L24230GJ2015PLC085451



Date: May 29, 2023

To, Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra East, Mumbai – 400051

Dear Sir,

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

# Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In Compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification no. SEBI/LAD-NRO /GN/2016-17/001 dated May 25, 2016 and circular no. CIR/CFD /CMD /56/2016 dated May 27, 2016, we hereby declare that the Statutory Auditors of the Company, M/s. Keyur Shah & Co. Chartered Accountants, (FRN: 141173W) have issued an Audit Report with unmodified opinion on the Standalone & Consolidated Audited Financial Results of the Company for the half year and year ended March 31, 2023.

You are requested to take the same on record. Thanking You, Yours Faithfully, For, Sotac Pharmaceuticals Limited Sharedkumar Dechrethbhai Patel

Sharadkumar Dashrathbhai Patel Chairman and Managing Director DIN: 07252252

Place: Ahmedabad



CA Keyur Shah FCA, B.Com, ISA, FAFP Certified

Independent Auditor's Report on Annual Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Sotac Pharmaceutical Limited (Erstwhile known as Sotac Pharmaceuticals Private limited) Plot No PF-21, Sanand GIDC-II, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad Gujarat- 382110

Opinion

We have audited the accompanying standalone annual financial results ('the Statement') of **Sotac Pharmaceutical Limited (Erstwhile known as Sotac Pharmaceutical Private Limited)** ('the Company') for the year ended 31st March 2023, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us the statement:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and other financial information for the year ended 31st March, 2023.

## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

303, Shitiratna, B/s. Radisson Blu Hotel, Nr. Panchvati Circle, Ambawadi, Ahmerabad-380005. Guarat, INDIA. Ph. : +91 79 48999595, M. : +91 999 8484 564 • Website : www.keyurshahca.com D ACCOV E-mail : keyur@keyurshahca.com, ca.keyurshah2015@gmail.com

#### Responsibilities of Management and those Charged with Governance for the Statement

This financial results has been prepared on the basis of the annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Accounting Standard prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

## Auditor's Responsibilities for the Audit of the Statement

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matters**

The statement includes the half yearly results for the year ended 31st March, 2023 being the balancing figure between audited figures in respect of the full financial year and the published un-audited figures in respect of 1st half year of the current financial year.

For, Keyur Shah & Co. **Chartered Accountants** UR SHAH F.R.No. 141173W SHIP NO Keyur Shah ED ACCOU

Proprietor M. No. 153774 UDIN :- 23153774BGWLVH1190

Date: - 29<sup>th</sup> May, 2023 Place:- Ahmedabad

#### SOTAC PHARMACEUTICALS LIMITED (Formally known as Sotac Pharmaceuticals Private Limited) Plot No PF-21, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110

CIN No.U24230GJ2015PLC085451

# Statement of Audited Standalone Financial Result for the half year and year ended on 31st March, 2023

		(INR in lakhs, except Earning per Share Value)				
	Particulars	Half Year Ended			Year Ended	
		31-03-23	30-09-22	31-03-22	31-03-23	31-03-22
		Audited	Audited	Audited	Audited	Audited
6	Revenue from Operations	2,723.55	3,074.73	3,924.59	5,798.28	7,315.1
ĮI.	Other Incomes	13.00	11.31	2.89	24.31	20.76
111.	Total Income (I + II)	2,736.55	3,086.04	3,927.48	5,822.59	7,335.93
v.	Expenses:					
	Cost of Materials Consumed	2,197.19	2,075.15	2,929.66	4,272.34	5,616.5
	Purchase of Stock in Trade	34.42	18.22	26.52	52.64	26.7
	Changes in Inventories of Finished Goods and	1000 001	100 000	100 A 100	124.2.201	
	Work-in-Progress	(289.82)	(28.56)	(51.94)	(318.38)	(45.3
	Employee Benefit Expenses	146.41	- 146.26	194.90	292.67	287.3
	Finance Costs	43.83	42.30	28.85	86.13	55.0
	Depreciation and Amortization Expense	88.64	73.89	61.70	162.53	112.6
	Other Expenses	321.46	356.74	550.32	678.21	814.1
	Total Expenses	2,542.13	2,684.00	3,740.01	5,226.14	6,867.1
V.	Profit/ Loss before Exceptional Items and Tax (III - IV)	194.42	402.04	187.47	596.45	468.76
		134.42	402.04	201.47	550.15	400.70
	Exceptional Items					
	Prior Period Adjustments	-				
VI.	Exceptional Items	-	-	-	-	-
VII.	Profit before Extraordinary Items and Tax (V - VI)	194.42	402.04	187.47	596.45	468.70
VIII	Extra Ordinary Items					1.
X.	Profit before Tax (VII+VIII)	194.41	402.04	187.47	596.45	468.76
х.	Tax Expense:			24.5 N CH		
	(1) Provision for Income Tax			10000		
	Current Income Tax	55.28	113.11	67.16	168.39	142.5
	(2) Deferred Tax (Assets) / Liabilities	(1.27)	(20.22)	(19.29)	(21.49)	3.2
XI.	Profit/ (Loss) for the period (IX-X)	140.40	309.15	139.60	449.55	329.55
-	Details of Equity Share Capital		ner en			
	Paid up Equity Share Capital	805.00	230.00	230.00	805.00	230.0
	Face Value of Equity Share Capital (Per Share)	10.00	10.00	10.00	10.00	10.00
	Details of Debts Securities	10.00	10.00	10.00	10.00	10.00
	Paid Up Debts Capital					1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
	Face Value of Debts Securities					T. 1
	Reserve Excluding Revalution Reserves as per Balance					
	Sheet of Previous Year	346.98	782.42	479.91	346.98	479.9
XII.	Earnings Per Equity Share					
	(1) Basic	1.74	13.44	6.07	5.58	14.3
	(2) Diluted	1.74	13.44	6.07	5.58	14.3
	(3) Adjusted EPS (Bouns Effect)	1.74	3.84	1.73	5.58	4.0

\* The earning per share for the half year ended has not been annualised. The Accompanying Notes Form Part of audited Financial Results

Place: Ahmedabad Date: 29-05-2023



For, Sotac Pharmaceuticals Limited

Sharadkumar Patel Chairman cum Managing Director Din No-07252252

Selor.

# SOTAC PHARMACEUTICALS LIMITED

(Formally known as Sotac Pharmaceuticals Private Limited)

Plot No PF-21, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110

## CIN No.U24230GJ2015PLC085451 Notes for Standalone Financial Results

1 The above audited Standalone Financial Results of Sotac Pharmaceuticals (the company) for the half year ended 31st March, 2023 and

year ended 31st March, 2023 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their

respective meeting held on 29th May, 2023. Mr Sharadkumar Dashrathbhai Patel, Chairman Cum Managing Director and Mr. Dineshkumar

Babulal Gelot, Whole Time Director of the Company authorised by the board of directors ro sign the financial results.

- 2 The Statutory auditors have carried out statotory audit of the above fianancial results of the company and have expressed and unmodified opinion these results.
- 3 The Standalone Financial Results are prepared in acordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable.
- 4 The statement includes the results for the half year ended 31st March, 2023 being the balanced figure between audited figures in respect of the full financial year and the audited figures in respect of 1st half year of the current financial year.
- 5 Company is mainly engaged in manufacturing of of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.
- 6 The Company alloted of 57,50,000 bonus equity shares of Rs. 10/- each as fully paid- up against existing 23,00,000 equity shares of Rs.10/- each to the existing shareholders of the Company in the ratio of 5 : 2 (5 new equity shares of Rs. 10/- each fully paid up for each 2 exiting equity share of Rs. 10/- each fully paid-up).

7 The company had made an initial public offering (IPO) of 30,00,000 equity shares of face value of Rs. 10/- each fully paid up for cash at a

price of Rs. 111/- per equity share(including share premium of Rs. 101 per equity share) aggregating to Rs.3330.00/- Lakhs. The

aforementioned equity shares of the company alloted as on 10th April, 2023 and got listed on NSE Emerge Platform on 13th April, 2023.

- 8 Initial Public offering of the company was initiated on 29th March, 2023 till 3rd April, 2023 the, company had received RS 947.05 Lakhs application money from anchore investors which has been shown under the head share application money pending allotement in the balance sheet.
- 9 The management is in process of identifying parties which are covered under MSME. The amount relating to MSME are disclosed to the extent identified.
- 10 Previous year's/period's figure have been regrouped/rearranged wherever necessary.
- 11 In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above results have been reviewed by the Statutory Auditors of the Company.

Place: Ahmedabad Date: 29-05-2023



For, Sotac Pharmaceuticals Limited

Sharadkumar Patel Chairman cum Managing Director Din No-07252252

Spersh

(Formally known as S Plot No PF-21, Nr. ACME Pharam, Op	J24230GJ2015PLC0854	Private Limited) nd GIDC-II, Ahmedabad-38 151	
Addited Standalone Asse	to and clashiftes a	(INR in lakhs, unless of	
Particulars		31-03-23	31-03-22
-1		Audited	Audited
LEQUITY AND LIABILITIES			
1) Shareholder's Funds			
(a) Share Capital		805.00	230.0
(b) Reserves and Surplus		346.98	479.9
2) Share Application Money pending allotment		947.05	
3) Non-Current Liabilities			
(a) Long-Term Borrowings		659.35	97.0
(b) Deferred Tax Liability		-	17.0
(c) Long Term Provisions		8.56	-
4) Current Liabilities			
(a) Short-Term Borrowings		406.46	641.7
(b) Trade Payables	i-		
(i) Total outstanding dues of micro enterprises and s	mall enterprises	439.10	1,172.4
(ii) Total outstanding dues of creditors other than mi	icro optorpricos		
and small enterprises	icro enterprises	1,380.41	805.1
(c) Other Current Liabilities		286.40	24.0
(d) Short-Term Provisions		198.98	162.4
TOTAL		5,478.29	3,629.8
To the		5,470.25	5,025.0
I. ASSETS			
1) Non-Current Assets			
(a) Property, Plant & Equiptment and Intangible Assets			
(i) Property, Plant & Equiptment		1,408.65	879.2
(ii) Intangible Assets		0.33	0.5
(iv) Capital Work In Progress		4.06	
(d) Deferred Tax Assets (Net)		4.40	
(e) Non- Current investment		400.21	
2) Current Assets			
(a) Inventories		958.11	539.4
(b) Trade Receivables		1,149.65	1,254.1
(c) Cash and Cash Equivalents		959.84	2.7
(d) Short-Term Loans and Advances		1.00	194.6
(e) Other Current Assets		592.04	759.1
TOTAL	The second second	5,478.29	3,629.8

The Accompanying Notes Form Part of audited Financial Results

Place: Ahmedabad Date: 29-05-2023

E C 20GUJARA

For, Sotac Pharmaceuticals Limited

Shart-

Beent

Sharadkumar Patel Chairman cum Managing Director Din No-07252252

# SOTAC PHARMACEUTICALS LIMITED

(Formally known as Sotac Pharmaceuticals Private Limited)

Plot No PF-21, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110 CIN No.U24230GJ2015PLC085451

Audited Standalone Cash Flow Statement for the Year ended on 31st March, 2023

PARTICULARS	(INR in lakhs, unless o	otherwise stated)
	31-03-2023	31-03-2022
	Audited	Audited
Cash Flows from Operating Activities		
Net Profit before tax and Extraordinary items	596.45	468.76
Adjustments for :		
Depreciation	162.52	112.68
Reversal of Previous year Tax	2 S S S S S S S S S S S S S S S S S S S	(54.41
Loss on sale of Investments in Sotac Healthcare Pvt. Ltd.		183.60
Prior Period Adjustment	(7.47)	
Interest Expense	86.14	55.00
Interest & Dividend Income	(2.93)	(2.53
Operating Profit before Working Capital Changes	834.71	763.10
Adjustments for :		
(Increase)/Decrease in Trade Receivables	104.45	(627.11
(Increase)/Decrease in Inventory	(418.65)	(159.59
Increase/(Decrease) in Other Current Assets	167.07	(377.89
(Increase)/Decrease in Short Term Loans and Advances	193.66	(181.66
Increase/(Decrease) in Trade Payables	(158.12)	927.58
Increase/(Decrease) in Other Current Liabilities	262.33	16.98
Increase/ (Decrease) in Short Term Provision & Other Liabilities	36.55	139.30
Cash Generated from Operations	1,022.00	500.71
Tax Paid ( net of refund)	(168.39)	(142.50
Net Cash from Operating Activities	853.61	358.21
Cash Flows from Investing Activities		
Addition in Propery, Plant and Equipments and Intagible Assets	(704.13)	(350.43
Disposals of Propery, Plant and Equipments and Intagible Assets	8.35	-
Purchase of Investment in Sotac Healthcare Pvt Ltd.	(400.21)	20.40
Interest income	2.93	2.53
Net Cash from Investing Activities	(1,093.06)	(327.50
Cash Flows from Financing Activities		and the second
Share Capital & Securities Premium	947.05	
Increase in in Long Term Borrowings	562.34	(570.06
Decrease in of Short Borrowings	(235.28)	640.83
Decrease in long term Provisions	8.56	
Finance Cost	(86.14)	(55.00
Dividend paid on Equity shares	(00.11)	(46.00
Net Cash from Financing Activities	1,196.53	(30.23
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	957.08	0.48
Cash and Cash Equivalents at the beginning	2.76	2.28
Cash and Cash Equivalents at the end (D+E)	959.84	2.20


Notes:-

 $\mathcal{T}_{i}$ 

1 Cash Flow statement has been Prepared as per the indirect method as set out/in accordance with accounting statndard 3 related to Cash Flow Statement.

2 Previous Year Figures have been regouped and rearranged as and when applicable.

Place: Ahmedabad Date: 29-05-2023



For, Sotac Pharmaceuticals Limited

Any

Sharadkumar Patel Chairman cum Managing Director Din No-07252252



CA Keyur Shah FCA, B.Com, ISA, FAFP Certified

Independent Auditor's Report on Annual Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Sotac Pharmaceutical Limited (Erstwhile known as Sotac Pharmaceuticals Private limited) Plot No PF-21, Sanand GIDC-II, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad Gujarat- 382110

#### Opinion

We have audited the accompanying consolidated annual financial results ('the Statement') of **Sotac Pharmaceutical Limited (Erstwhile known as Sotac Pharmaceuticals Private limited)** ('the Company') and its subsidiary **Sotac Healthcare Private limited, Sotac Research Private Limited, Sotac Life science Private Limited.** (the holding company and its subsidiary together referred to as "group") for the year ended 31st March 2023, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us the statement:

- (i) Includes the result of following subsidiary:
  - a) Sotac Healthcare Private limited
  - b) Sotac Research Private Limited
  - c) Sotac Life science Private Limited
- (ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and other financial information for the year ended 31st March, 2023.

## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the consolidated financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





# Responsibilities of Management and those Charged with Governance for the Statement

These consolidated financial results has been prepared on the basis of the annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Accounting Standard prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

# Auditor's Responsibilities for the Audit of the Statement

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due
  to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit
  evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting
  a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may
  involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting
  and, based on the audit evidence obtained, whether a material uncertainty exists related to events or
  conditions that may cast significant doubt on the Company's ability to continue as a going concern. If
  we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report

to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our sophing of our conclusions are based on the audit evidence obtained up to the date of our auditor's

report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the
  disclosures, and whether the financial results represent the underlying transactions and events in a
  manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the
  entities within the Group and its associates and joint ventures of which we are the independent auditors
  to express an opinion on the Statement We are responsible for the direction, supervision and
  performance of the audit of the financial information of such entities included in the Statement of which
  we are the independent auditors.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

# **Other Matters**

- d) The consolidated Financial Results include the audited Financial Results of Sotac Healthcare Private limited, Sotac Research Private Limited, Sotac Life science Private Limited subsidiaries, whose Financial Statements/Financial Results/ financial information reflect Group's share of total assets is Rs. 2,101.33 Lakhs as at 31st March, 2023, Group's share of total income of Rs. 2,015.13 Lakhs and Group's share of total net profit after tax of Rs. (220.91) Lakhs for the period from 1st April, 2022 to 31st March, 2023 respectively, as considered in the consolidated Financial Results, which have been audited by us.
- e) Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.

For, Keyur Shah & Co. Chartered Accountants F.R.No. 141173W

IR SHAH **Keyur Shah** Proprietor ED ACCOU M. No. 153774

UDIN: 23153774BGWLVI7838

Date: 29<sup>th</sup> May, 2023 Place: Ahmedabad

SOTAC PHARMACEUTICALS LIMITED	
(FORMALLY KNOWN AS Sotac Pharmaceuticals Private Limited)	

CIN: U24230GJ2015PLC085451

#### Plot No PF-21, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-11, Ahmedabad-382110

Part-1

## Statement of Audited Consolidated Financial Results for the half year and year ended 31st March, 2023

	o. Particulars	(INR in lakhs, unless otherwise stated)				
		Half Year Ended		Year Ended		Ended
Sr No.		31-03-2023	30-09-2022	31-03-2022	31-03-2023	31-03-2022
		Audited	Audited	(Refer Note No. 2)	Audited	(Refer Note No. 2
1	Revenue From Operations					
	Net sales or Revenue from Operations	3,773.49	3,974.83		7,748.32	
	Other Income	14.66	20.30	-	34.96	
	Total Income	3788.15	3995.13		7783.28	-
Ш	Expenses					
	Cost of Material Consumed	3,019.27	3,095.96		6,115.23	-
	Purchase of Stock in Trade	34.42	18.22		52.64	
	Change in WIP	(300.38)	(140.58)		(440.96)	
	Employee Benefit Expenses	219.10	203.60		422.70	1
	Finance Costs	91.31	106.24		197.55	
	Depreciation & Amortisation	116.65	111.13		227.78	-
	Other Expenses	416.16	457.53		873.69	
	Total expenses	3,596.53	3852.1		7,448.63	
	Profit/(loss) before exceptional items and tax	191.62	143.03		334.65	-
-	Exceptional items	-	58.02	-	58.02	-
HI	Profit before tax	191.62	201.05	-	392.67	-
IV	Tax Expense:			1.576.91.9		
	Current Tax	55.28	113.11		168.39	
	Deferred Tax Asset/ (Liability)	9.25	(13.58)		(4.33)	
	Net Profit / (Loss) for the period	127.09	101.52		228.61	
	Details of Equity Share Capital	127.05				The second s
	Paid up Equity Share Capital	805.00	230.00		805.00	
	Face Value of Equity Share Capital (Per Share)	10.00	10.00		10.00	
	Details of Debts Securities	-			15-11-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	-
	Paid Up Debts Capital	-				-
	Face Value of Debts Securities	-				
	Reserve Excluding Revalution Reserves as per Balance Sheet of Previous Year	193.88	645.20		193.88	
	Earning per equity share:	To state to				
	(1) Basic	1.58	4.41		2.84	
	(2) Diluted	1.58	4.41		2.84	-
	(3) Adjsuted EPS (Bouns Effect)	1.58	1.26	-	2.84	-

#### Notes for Financial Results

1 The above audited Consolidated Financial Results of Sotac Pharmaceuticals Limited (the company) for the half year ended 31st March, 2023 and year ended 31st March, 2023 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 29th May, 2023.Mr Sharadkumar Dashrathbhal Patel, Chairman Cum Managing Director and Mr. Dineshkumar Babulal Gelot, Whole Time Director of the Company authorised by the board of directors ro sign the financial results.

2 In the FY 2021-22, Company had no subsidiary - holding relationship, hence previous year figure not shown in the financial results.

3 The Consolidated Financial Results are prepared in acordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule

7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable.

4 The Statutory auditors have carried out statotory audit of the above fianancial results of the company and have expressed and unmodified opinion these results.

5 The statement includes the results for the half year ended 31st March, 2023 being the balanced figure between audited figures in respect of the full financial year and the audited figures in respect of 1st half year of the current financial year.

## SOTAC PHARMACEUTICALS LIMITED

#### (FORMALLY KNOWN AS Sotac Pharmaceuticals Private Limited)

CIN: U24230GJ2015PLC085451

#### Plot No PF-21, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-11, Ahmedabad-382110

Part-1

#### Statement of Audited Consolidated Financial Results for the half year and year ended 31st March, 2023

- 6 Group is mainly engaged in manufacturing of of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Beta-Lactam Formulation Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.
- 7 The Holding Company alloted of 57,50,000 bonus equity shares of Rs. 10/- each as fully paid- up against existing 23,00,000 equity shares of Rs.10/- each to the existing shareholders of the Company in the ratio of 5 : 2 (5 new equity shares of Rs. 10/- each fully paid up for each 2 exiting equity share of Rs. 10/- each fully paid-up).
- 8 The holding company had made an initial public offering (IPO) of 30,00,000 equity shares of face value of Rs. 10/- each fully paid up for cash at a price of Rs. 111/per equity share(including share premium of Rs. 101 per equity share) aggregating to Rs.3330.00/- Lakhs. The aforementioned equity shares of the company alloted as on 10th April, 2023 and got listed on NSE Emerge Platform on 13th April, 2023.
- 9 Initial Public offering of the holding company was initiated on 29th March, 2023 till 3rd April, 2023 the, company had received RS 947.05 Lakhs application money

from anchore investors which has been shown under the head share application money pending allotement in the balance sheet.

10 The management is in process of identifying parties which are covered under MSME, The amount relating to MSME are disclosed to the extent identified.

- 11 During the year Company had subscribed 5100 Equity share at Rs 10 each by investing RS 0.51 Lakhs of Sotac Life Sciences Limited.
- 12 During the year Company had invested 389.70 Lakhs in aggregate in Sotac Healthcare Private Limited by purchasing 1500000 equity shares at RS10/- having Face Value of Rs 10/- per share, 2040000 Equity Shres at Rs 3/- per share having face value of Rs 10/- per share and by Conversion of Loan amounting to Rs 1785000 into 178500 equity shares having face value of Rs 10/- at par.
- 13 During the year Company had invested in Sotac Research Private Limited by buying 100000 equity shares of Rs 10/- per share amounting to Rs 10 Lakhs in aggregate.
- <sup>14</sup> Previous year's/period's figure have been regrouped/rearranged wherever necessary.
- 15 In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above results have been reviewed by the Statutory Auditors of the Company.

#### 16 Following are the detils of the subsidiaries consolidated in these financial statement:

Name Of Company	Relationship	Country of Incorporation	% Equity Interest ( As at 31St March, 2023)
Sotac Research Private Limited	Subsidary	India	99.99%
Sotac Healthcare Private Limited	Subsidary	India	71.00%
Sotac Lifesciences Private Limited	Subsidary	India	51.00%



For, Sotac Pharmaceuticals Limited

SO

Dineshkumar Gelot Wholetime Director Din No-07252132

Place : Ahmedabad Date : 29-05-2023 Sharadkumar Patel Chairman cum Managing Director Din No-07252252

	SOTAC PHARMACEUTICALS LIMI (FORMALLY KNOWN AS Sotac Pharmaceutical CIN: U24230GJ2015PLC08545	s Private Limited)
	Plot No PF-21, Nr. ACME Pharam, Opp. Teva Pharam, Sanan Part- 2	
	Audited Consolidated Statement of Assets & Liablities	as at 31st March, 2023
Sr		(INR in lakhs, unless otherwise stated)
	Particulars	As At
No.		31-03-2023
		Audited
(A)	EQUITY AND LIABILITIES	
1	Shareholder's Funds	
a	Share Capital	805.0
b	Reserves and Surplus	193.8
	Total Equity	998.8
2	Share application money pending allotment	947.0
3	Minority Interest	22.0
4	Non-Current Liabilities	
a	Long Term Borrowing	776.8
b	Deferred Tax Liabilities (Net)	27.3
С	Long Term Provisions	9.5
	Total Non-Current Liabilities	814.1
5	Current Liabilities	
а	Short-Term Borrowings	1,426.5
b	Trade Payable	
	i) Total outstanding dues of micro enterprises and small enterprises	527.3
	ii) Total outstanding dues of creditors other than micro enterprises and small	
	enterprises.	2,012.0
с	Other Current Liabilities	408.7
d	Short-Term Provisions	206.0
	Total Current Liabilities	4,581.
	TOTAL EQUITY & LIABILITIES	7,363.
(8)	ASSETS	
1	Non-Current Assets	
a	Property, Plant & Equipment & Intangible Assets	
	i) Property, Plant & Equipment	2,400.5
	ii) Intangible Assets	0.3
	iii) Capital work In -Progress	4.
	iv) Goodwill on Consolidation	190.
d	Long Term Loans and Advances	54.
	Total Non-Current Assets	2,650.1
2	Current Assets	
в	Inventories	1,364.
b	Trade Receivables	1,494.
С	Cash and Cash Equivalents	968.
d	Short-Term loans And Advances	1.
C	Other Current Assets	886.
-	Total Current Assets	4,713.
	TOTAL ASSETS	7,363.9



For, Sotac Pharmaceuticals Limited

Shap

Dineshkumar Gelot Wholetime Director

Din No-07252132

Bser

Place : Ahmedabad Date : 29-05-2023

1

Sharadkumar Patel Chairman cum Managing Director Din No-07252252

	(FORMALLY KNOW	IN AS Sotac Pharmaceuticals Private	Limited)	
1.1	CII	N: U24230GJ2015PLC085451		
	Plot No PF-21, Nr. ACME Phara	am, Opp. Teva Pharam, Sanand GIDC-11, Al	medabad-382110	
		Part- 3		
	Audited Consolidated Cash	n Flow Statement for the Year Ended on 31s	t March, 2023	
-		Lawrence as the		Year ended
Sr No.		Particulars		31-03-2023
	Cash flow from opporting activities			Audited
	Cash flow from operating activities Net Profit before tax paid			392.6
				332.0
	Adjustments for :			1.23.25
	Depreciation and amortization			227.7
	Interest income			(4.6
	Finance Cost			197.5
	Prior Period Adjustment			11.9
	Operating profit before working capital changes	(a)		825.3
	Adjustment for Changes in Working Capital :			1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
	Increase in Trade Payables			(478.49
	Increase in Other Current Liabilities			228.65
	Decrease in Short term Provisions			38.10
	Increase in Inventories			(446.53
	Increase in Trade Receivables	5-		381.1
	Increase in Short Term Loans and Advances			192.7
	Increase in Other Current Assets			241.6
	Operating profit after working capital changes	(6)	Sector Sector	157.2
	Cash generated from Operations	(b) ( a + b)		982.6
	Taxes paid ( net of refund)	( 4 + 0)		(168.3
	Net Cash generated from Operations	(A)		814.2
I.	Cash Flow from Investing Activities			2.200
	Addition in Propery, Plant and Equipments and Int	agible Assets		(899.9
	Disposals of Propery, Plant and Equipments and In	tagible Assets		131.4
	Purchase of investment in Sotac Healthcare Pvt Ltd	í.		(400.2)
	Decrease in of Loans and advacnes			1.6
	Interest income			(0.2
	Net Cash generated / ( used ) in Investing Activit	ies (B)		(1,167.3)
11.	Cash Flow from Financing Activities Increase in in Long Term Borrowings			65.3
	Decrease in of Short Borrowings			310.7
	Decrease in long term Provisions			8.5
	Finance Cost			(197.5
	Proceeds from Share Application Money received			947.0
	Cash Flow from Financing Activities			
v.	Net Cash Used in Financing Activities	(C)	CONTRACTOR OF THE	1,134.1
Ι.	Net Increase in Cash and Cash Equivalents (	A + B + C )		960.5
/1.	Cash and Cash Equivalents as on 1st April, 2022			7.6
	Cash and Cash equivalent at the end of the year			968.1
	cash and cash equivalent at the end of the year			900.1
	Cash Flow Statement has been prepared under the	indirect method as set out in the accounting	Standards (AS 3) "Cash Flo	ow Statement"
1.0	the state of the s	marcer method as set out in the decounting	, standards (no s) cashing	on statement
2	Previous years's figures have been regrouped / recl	assified/rearranged wherever applicable		
		EII	For, Sotac Pharmaceu	ticals Limited
		ACEUTIO	D.d.	Freior.
		C12015 7	wager	Esoe
		5000000000	Sharadkumar Patel	Dineshkumar Gelot
	Place : Ahmedabad	78 -19-1	Chairman cum	Wholetime Director
	These s Particulated	GUJARAI &	Managing Director	whole time birector
	Date : 29-05-2023	1.1.2. 1.5.15	Din No-07252252	Din No-07252132